Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3

Tempest Therapeutics, Inc.

2024-Q1 EPS reported -$0.36

Cash $32.3M at March 31, 2024; expects runway into Q2 2025.
Net loss $7.9M ($0.36/sh) vs $7.6M ($0.55/sh) YoY; R&D $4.3M, G&A $3.6M.
TPST-1120 plans to advance to pivotal Phase 3 in first-line HCC, subject to FDA feedback.
TPST-1495 planned for Phase 2 in FAP in 2024 under NCI funding; updated data expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $7.9 million, EPS $0.36.

Period: the quarter ended March 31, 2024
Net income: $7.9 million
EPS: $0.36
Result: reported results

Exact text from the filing

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-057047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.